Contineum Therapeutics Announces Q2 2025 Financial Results and Upcoming Earnings Event

Contineum Therapeutics (NASDAQ: CTNM) released its financial performance for the second quarter of 2025. The company's stock closed at $6.00, reflecting a $0.20 increase, or 3.45%, by the end of regular trading hours. In extended trading, the price was slightly higher at $6.04, up by $0.04 or 0.67%, as of 7:28 PM Eastern. The firm reported an actual EPS of -$0.62, missing the consensus estimate of -$0.56 by $0.06. Revenue data for the quarter was not available, and the anticipated revenue was $7.50 million. Year-over-year revenue growth figures have not been disclosed. Looking ahead, Contineum Therapeutics is scheduled to announce its Q2 2025 earnings on August 12, 2025. A conference call is planned for August 13, 2025, at 4:00 AM Eastern Time. Investors can expect detailed financial metrics, transcripts, and audio recordings following the event. The company continues to advance its clinical pipeline, including updates on its Phase 1b PET trial of PIPE-791 and other key development milestones. Contineum Therapeutics specializes in developing innovative oral therapies targeting neurological, inflammatory, and immunological conditions with significant unmet medical needs. Headqua...